Liver-Test Abnormalities in the CBD Epilepsy Series Included Resolution Without Stopping Treatment
The adult epilepsy series reported liver-function abnormalities in seven patients, with increases below twice the normal value. Most resolved without a treatment adjustment, while one resolved after valproic acid was tapered.
The severity and course belonged in the result
Seven of 37 patients had recorded abnormal liver-function results. Six resolved without treatment adjustment; the remaining case resolved after valproic acid reduction. These observations provide more information than an undifferentiated statement that liver abnormalities occurred.
A treatment change does not prove one causal explanation
Resolution after reducing valproic acid is relevant to a possible contribution from concomitant therapy. It does not establish that valproic acid alone caused the abnormality, or that CBD played no role. The uncontrolled retrospective series cannot separate every drug interaction, patient characteristic and time-related influence.
A laboratory signal is not equivalent to liver failure
The report did not describe these observations as proof of severe clinical liver injury. Equally, resolution of the recorded abnormalities does not establish absence of hepatic risk in other populations or regimens. An evidence-based summary preserves the magnitude, number affected and clinical course without either minimizing the laboratory finding or enlarging it into an unsupported diagnosis. This is a treatment-experience observation in a selected severe-epilepsy cohort, not a universal safety estimate for all CBD products.
Related analysis: the source’s broader findings and limitations.
